[Effectiveness of synthetic calcitonin derivative (elcatonin) on the bone pain and serum calcium concentration in multiple myeloma].
Fifteen patients (8 male and 7 female) with multiple myeloma, who were admitted to our hospital between July 1986 and August 1988 and suffering from pain and hypercalcemia, were treated with synthetic calcitonin derivative (elcatonin: ECT). ECT was administered intravenously at a dose of 10-640 units twice daily. Seven patients were treated with ECT (ECT group), and eight patients received combination treatment with ECT and other form of chemotherapy (combination group). With regard to the pain score (PS), significant analgesic effects in both groups were observed during 1-4 week treatments (p less than 0.05). There were no significant differences in PS between two groups. Serum calcium levels in the combination group at 1 and 4 weeks were significantly lower than the initial value (p less than 0.05). Hypocalcemia was not seen in any of the patients. Urinary excretion of calcium at 1 week in ECT group was higher than the initial value (p less than 0.05). The observed toxicities of ECT were slight nausea and vomiting in only 2 patients. These findings suggest that ECT is an useful agent for the treatment of pain and hypercalcemia accompanied with multiple myeloma.
Hirota
Y
Y
Dept. of Internal Medicine, Matsuyama Red Cross Hospital.
Kondou
S
S
Okamura
H
H
Ikematsu
W
W
Aso
T
T
Kounoue
E
E
Matsumoto
I
I
Kuwashima
K
K
Kajiyama
K
K
D000368:Aged; D000369:Aged, 80 and over; D001842:Bone and Bones; D002116:Calcitonin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002118:Calcium / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000503:physiopathology; D010147:Pain Measurement; D010148:Intractable Pain / Q000188:drug therapy*
D002116:Calcitonin; D002118:Calcium; C012755:elcatonin